<DOC>
	<DOCNO>NCT00326417</DOCNO>
	<brief_summary>The purpose current study continue optimize conditioning regimen high-risk patient severe aplastic anemia transplant marrow HLA-compatible unrelated donor . Specifically , study determine whether addition fludarabine condition regimen previously describe Deeg et al . permit reduction CY dose , point sustain hematopoietic engraftment survival maintain ( improve ) , frequency major regimen-related toxicity ( RRT ) early death reduce .</brief_summary>
	<brief_title>Fludarabine-based Conditioning Severe Aplastic Anemia ( BMT CTN 0301 )</brief_title>
	<detailed_description>BACKGROUND : Aplastic anemia ( AA ) remain life-threatening illness . Treatment option include supportive care ( transfusion , growth factor , etc . ) , immunosuppression therapy stem cell transplantation . Only latter two favorably impacted natural history disease . The prognosis AA patient , particularly severe aplastic anemia ( SAA ) , define Camitta et al. , fail respond immunosuppressive therapy ( IS ) relapse initial response IS poor . Although many patient support short term growth factor , transfusion possibly rechallenged successfully IS , cumulative morbidity mortality infection , hemorrhage transfusion-related complication substantial . While allogeneic bone marrow transplantation potentially curative AA , 25 % patient human leukocyte antigen ( HLA ) -identical sibling donor . Cyclophosphamide ( CY ) -antithymocyte globulin ( ATG ) recommend preparative regimen choice sibling donor transplant . Results bone marrow transplantation alternative donor , match unrelated donor mismatch related donor AA patient fail IS , largely unsatisfactory . The cyclophosphamide-ATG conditioning regimen prove inadequate ensure engraftment allogeneic transplant match , unrelated donor AA . This major reason total body radiation ( TBI ) add condition regimen . Graft failure serious frequently life-threatening fatal event follow match unrelated donor ( MUD ) allografts aplastic anemia . It immunologically mediate event . Risk factor graft failure include use HLA nonidentical unrelated donor , poor marrow nucleate cell dose well prolonged transfusional support prior BMT ( increase probability patient sensitization multiple antigen ) . While patient may achieve autologous hematopoietic recovery , prolong pancytopenia common infection-related morbidity mortality substantial . Reconditioning second allograft different donor frequently successful . While addition TBI intensive pre-transplant conditioning lead sizable improvement engraftment rate , come price , particularly adult patient . Transplant-related toxicity major frequent problem . Radiation-induced pulmonary toxicity particular common , usually form diffuse alveolar damage diffuse interstitial pneumonitis . In addition , Graft Versus Host Disease ( GVHD ) -related morbidity mortality patient also substantial . DESIGN NARRATIVE : The study prospective Phase I/II dose optimization study . All patient give fix dose ATG ( either thymoglobulin : 3 mg/kg IV daily x 3 ATGAM 30 mg/kg IV daily x 3 , Days -4 -2 ) , Fludarabine ( 30 mg/m^2 IV daily x 4 , Days - 5 -2 ) , TBI ( 200 cGy ( centigray ) linear accelerator le 20 cGy/min Day -1 ) . The start CY dose 150 mg/kg ( 50 mg/kg intravenously daily , Days -4 -2 ) , de-escalated depend engraftment toxicity . The Phase I portion trial ( maximum 24-27 patient ) test four dose level CY adequate safety graft retention . The Phase II portion trial refines dose selection allocate additional 70 patient optimal dose , two-year post-transplant survival assess . The combined enrollment Phase I II total 94 patient . The study prospective single-arm Phase I/II dose-selection evaluation study . The study seek optimal dose level CY base assessment graft failure , toxicity early death 100 day follow-up post-transplant . A brief synopsis give . Phase I - Test Each Dose Adequate Safety Graft Retention 1 . Proceed high dose ( 150 mg/kg CY ) low dose ( 0 mg/kg CY ) , treat minimum six patient dose . 2 . Evaluate 100-Day outcome toxicity , death graft failure patient enrol current dose , stop criterion meet . 3 . If three graft failure current dose , current dose lower dos close enrollment . 4 . If five severe regimen-related toxicity and/or early death current dose , current dose close enrollment , next low dose test . 5 . Dose de-escalation cease four dos test closed enrollment . Phase II - Refine Dose Selection Allocate Patients Optimal Dose 1 . Treat newly enrol patient desirable dose level remain open enrollment . This involve de-escalation , escalation , change dose . 2 . As patient completes observation period , evaluate 100-Day outcome graft failure , toxicity and/or early death patient , stop criterion meet . 3 . If excess ( accord criterion Table 5.8 ) graft failure , patient 's dose low dos close enrollment . 4 . If excess ( accord criterion Table 5.8 ) toxicity and/or early death , patient 's dose close enrollment . 5 . Re-evaluate desirability current dose level base 100-Day outcome toxicity and/or early death graft failure . 6 . Repeat step 1-5 54 patient enrol Phase II , dose level close enrollment . Dosage Levels CY : 3 Days ( Day -4 , -3 , -2 ) : Dose 50 mg/kg/day ; total dose 150 mg/kg ; dose level 3 2 Days ( Day -3 , -2 ) : Dose 50 mg/kg/day ; total dose 100 mg/kg ; dose level 2 1 Day ( Day -2 ) : Dose 50 mg/kg/day ; total dose 50 mg/kg ; dose level 1 0 Days ( None ) : No dose ; total dose ; dose level 0 There may wait period enrollment successive patient and/or cohort endpoint assessment . Under circumstance , final decision wait versus treat patient study make local transplant center .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients 65 year age time registration diagnosis SAA ; SAA define follow : 1 . Bone marrow cellularity le 25 % marrow cellularity le 50 % le 30 % residual hematopoietic cell 2 . Two three follow ( peripheral blood ) : neutrophil le 0.5 x 10^9/L ; platelet le 20 x 10^9/L ; reticulocyte less 20 x 10^9/L Patient must available unrelated donor 7/8 8/8 match HLAA , B , C , DRB1 antigen ; type DNA technique : intermediate resolution A , B , C , high resolution DRB1 ; HLADQ type recommend count match Patient and/or legal guardian able provide sign informed consent Matched unrelated donor must consent provide marrow allograft Patients adequate organ function measure : 1 . Cardiac : leave ventricular ejection fraction rest must great 40 % shorten fraction great 20 % 2 . Hepatic : serum bilirubin le 2x upper limit normal age per local laboratory ) ( exception isolate hyperbilirubinemia due Gilbert 's syndrome ) , alanine transaminase ( ALT ) aspartate transaminase ( AST ) less 4x upper limit normal age ( per local laboratory ) 3 . Renal : serum creatinine le 2x upper limit normal age ( per local laboratory ) 4 . Pulmonary : Forced expiratory volume 1 second ( FEV1 ) , force vital capacity ( FVC ) , carbon monoxide diffuse capacity ( DLCO ) ( correct Hb ) great 50 % predict ; patient pulse oxymetry perform , O2 saturation great 92 % Diagnosis Fanconi anemia must exclude patient young 18 year age diepoxybutane test peripheral blood comparable test marrow . Clonal cytogenetic abnormality associate myelodysplastic syndrome ( MDS ) acute myeloid leukemia ( AML ) marrow examination Diagnosis `` congenital '' aplastic anemia : DiamondBlackfan ; ShwachmanDiamond ; congenital amegakaryocytosis Symptomatic uncontrolled cardiac failure coronary artery disease Karnofsky performance status le 60 % Lansky le 40 % patient young 16 year old Uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical symptom ) Seropositive human immunodeficiency virus ( HIV ) Pregnant ( positive total HCG ) breastfeed Presence large accumulation ascites pleural effusion , would contraindication administration methotrexate GVHD prophylaxis Known severe lifethreatening allergy intolerance ATG cyclosporine/ tacrolimus Planned administration alemtuzumab ( Campath1H ) investigational agent alternative agent GVHD prophylaxis Concomitant enrollment Phase I study Positive patient antidonor lymphocyte crossmatch HLAA B mismatch transplant ; definition match Section 2.2.1 ; crossmatch would apply mismatch HLAA B , DRB1 HLAC Prior allogeneic marrow stem cell transplantation Patients prior malignancy except resect basal cell carcinoma treat carcinoma insitu ; cancer treat curative intent le 5 year previously allow unless approve Medical Monitor Protocol Chair ; cancer treat curative intent 5 year previously allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Severe Aplastic Anemia</keyword>
</DOC>